title: Use of the Medication Event Monitoring System to estimate medication compliance in patients with schizophrenia.
abstract: OBJECTIVE
  To determine the feasibility of using the Medication Event Monitoring System (MEMS) to estimate medication compliance in patients with schizophrenia or schizoaffective disorder.
  
  
  METHODS
  Fourteen of 35 consecutive patients admitted to a psychiatric inpatient hospital with schizophrenia or schizoaffective disorder who met eligibility requirements and gave informed consent.
  
  
  METHODS
  After random assignment to either risperidone or typical antipsychotic treatment, medication upon discharge from hospital was dispensed in a bottle with a MEMS cap which recorded the number of bottle openings and the date and time of each opening. The first 6 patients were asked to return monthly for data downloading. The next 8 were asked to return weekly during the first month and every 2 weeks thereafter; they were also paid $5 for returning each bottle.
  
  
  METHODS
  MEMS data collected over a 6-month period and hospital readmission data.
  
  
  RESULTS
  Patient medication compliance data were collected from 10 (71%) of 14 patients during the first month, from 7 (58%) of 12 (2 patients dropped out) during the second and from 5 (45%) of 11 (a third patient dropped out) during months 3-6. Mean compliance rates were 63% for the first month and ranged from 56% to 45% over the next 5. First-month compliance rates were significantly lower for those who were subsequently readmitted to hospital (n = 7) than for those who were not (p < 0.01).
  
  
  CONCLUSIONS
  Electronic monitoring devices can be used to estimate compliance with medication regimens in patients with severe schizophrenic disorders, but there are methodological improvements that can be made to increase data recovery and compliance, and these are discussed.
authors.affiliation: Department of Psychiatry, Yale University, New Haven, Conn., USA. Esperanza.Diaz@yale.edu
authors.forename: E
authors.initials: E
authors.lastname: Diaz
authors.forename: H B
authors.initials: HB
authors.lastname: Levine
authors.forename: M C
authors.initials: MC
authors.lastname: Sullivan
authors.forename: M J
authors.initials: MJ
authors.lastname: Sernyak
authors.forename: K A
authors.initials: KA
authors.lastname: Hawkins
authors.forename: J A
authors.initials: JA
authors.lastname: Cramer
authors.forename: S W
authors.initials: SW
authors.lastname: Woods
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D016903:Drug Monitoring / Q000295:instrumentation*; D004349:Drug Packaging; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance / Q000523:psychology; D010359:Patient Readmission; D011618:Psychotic Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D018967:Risperidone / Q000008:administration & dosage* / Q000009:adverse effects; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy*; D012646:Self Administration; D016312:Treatment Refusal / Q000523:psychology
chemical_list: D014150:Antipsychotic Agents; D018967:Risperidone